IGHE and Anosmia: Overall, we observed significant decreases in the frequency of exacerbations and hospitalization, anosmia, Ocs use, and SNOTT-22 scores, a significant increase in the ACT scores and FEV1%, and significant decreases in serum IgE and eosinophilic counts after 6 &12 months of dupilumab therapy compared to pre-biological treatment, respectively.